Nicotinamide Benzimidazolide Dinucleotides, Non-Cyclisable Analogues of NAD+

Philip Redpath; Jolanta Haluszczak; Simon J. Macdonald; Marie E. Migaud

doi:10.1055/s-0034-1379000

Synlett, Inhaltsverzeichnis

Synlett 2014; 25(16): 2331-2336
DOI: 10.1055/s-0034-1379000

letter

Nicotinamide Benzimidazolide Dinucleotides, Non-Cyclisable Analogues of NAD⁺

Authors

Philip Redpath

^aQueen’s University Belfast, John King Laboratory, School of Pharmacy, Lisburn Road, Belfast, BT9 7BL, Northern Ireland, UK Fax: +44(28)90247794 eMail: m.migaud@qub.ac.uk
Jolanta Haluszczak

^aQueen’s University Belfast, John King Laboratory, School of Pharmacy, Lisburn Road, Belfast, BT9 7BL, Northern Ireland, UK Fax: +44(28)90247794 eMail: m.migaud@qub.ac.uk
Simon J. Macdonald

^bGlaxoSmithKline, Stevenage, SG1 2NY, UK
Marie E. Migaud*

^aQueen’s University Belfast, John King Laboratory, School of Pharmacy, Lisburn Road, Belfast, BT9 7BL, Northern Ireland, UK Fax: +44(28)90247794 eMail: m.migaud@qub.ac.uk

Abstract

Alle Artikel dieser Rubrik

Abstract

Benzimidazole-based nucleotides and dinucleotides have been synthesised to increase the range of chemical tools available to probe the NAD⁺ biology space. They were examined for their reactivity in alkylation-type reactions, where they yielded unstable alkylated heteoaromatic adducts, both chemically and enzymatically. While unsuited for NAD⁺ cyclases, these NAD⁺ analogues could be viable substrates for non-adenine modifying NAD⁺-dependent enzyme classes.

Key words

nucleotides - benzimidazoribosyl nucleosides - phosphorylation - cyclic adenosine diphosphoribose - enzymes

Volltext

Referenzen

References and Notes
1 Guse AH. Curr. Med. Chem. 2004; 11: 847
2 Ogunbayo OA, Zhu Y, Rossi D, Sorrentino V, Ma J, Zhu MX, Evans AM. J. Biol. Chem. 2011; 286: 9136

3a Chini EN. Curr. Pharm. Design 2009; 15: 57
3b Malavasi F, Deaglio S, Funaro A, Ferrero E, Herenstein AL, Ortolan E, Vaisitti T, Aydin S. Physiol. Rev. 2008; 88: 841
3c Lee HC. Physiol. Rev. 1997; 77: 1133
3d Galione A. Science 1993; 259: 325
3e Galione A. Mol. Cell. Endocrinol. 1994; 98: 125
3f Lee HC. Annu. Rev. Pharmacol. Toxicol. 2001; 41: 317

4a Deaglio S, Mehta K, Malavasi F. Leuk. Res. 2001; 25: 1
4b Adebanjo OA, Anandatheerthavarada HK, Koval AP, Moonga BS, Biswas G, Sun L, Sodam BR, Bevis PJ, Huang CL, Epstein S, Lai FA, Avadhani NG, Zaidi M. Nat. Cell Biol. 1999; 1: 409
4c Orciani M, Trubiani O, Guarnieri S, Ferrero E, Di Primio R. J. Cell Biochem. 2008; 105: 905
4d Khoo KM, Chang CF. Int. J. Biochem. Cell Biol. 2002; 34: 43

5a Matrai Z. Hematology 2005; 10: 39
5b Deaglio S, Vaisitti T, Aydin S, Ferrero E, Malavasi F. Blood 2006; 108: 1135
5c Dürig J, Naschar M, Schmücker U, Renzing-Köhler K, Hölter T, Hüttmann A, Dührsen U. Leukemia 2002; 16: 30

6 Zhang FJ, Sih CJ. Bioorg. Med. Chem. Lett. 1996; 6: 2311

7a Guse AH. FEBS J. 2005; 272: 4590
7b Liu Q, Kriksunov IA, Moreau C, Graeff R, Potter BV. L, Lee HC, Hao Q. J. Biol. Chem. 2007; 282: 24825

8 Mort CJ. W, Migaud ME, Galione A, Potter BV. L. Bioorg. Med. Chem. 2004; 12: 475
9 Graeff R, Liu Q, Kriksunov IA, Kotaka M, Oppenheimer N, Hao Q, Lee HC. J. Biol. Chem. 2009; 284: 27629
10 Shuto S, Matsuda A. Curr. Med. Chem. 2004; 11: 827
11 Zhang FJ, Sih CJ. Tetrahedron Lett. 1995; 36: 9289

12a Zhang B, Bailey VC, Potter BV. L. J. Org. Chem. 2008; 73: 1693
12b Sethi JK, Empson RM, Bailey VC, Potter BV. L, Galione A. J. Biol. Chem. 1997; 272: 16358

13 Walseth TF, Lee HC. Biochim. Biophys. Acta 1993; 1178: 235
14 Bailey VC, Sethi JK, Fortt SM, Galione A, Potter BV. L. Chem. Biol. 1997; 4: 51
15 Moreau C, Wagner GK, Webber K, Guse AH, Potter BV. L. J. Med. Chem. 2006; 49: 5162
16 Zhang B, Wagner GK, Webber K, Garnham C, Morgan AJ, Galione A, Guse AH, Potter BV. L. J. Med. Chem. 2008; 51: 1623
17 Wagner GK, Guse AH, Potter BV. L. J. Org. Chem. 2005; 70: 4810
18 Wong L, Aarhus R, Lee HC, Walseth TF. Biochim. Biophys. Acta 1999; 1472: 555

19a Shuto S, Fukuoka M, Manikowsky A, Ueno Y, Nakano T, Kuroda R, Kuroda R, Matsuda A. J. Am. Chem. Soc. 2001; 123: 8750
19b Guse AH, Cakir-Kiefer C, Fukuoka M, Shuto S, Webber K, Bailey VC, Matsuda A, Mayr GW, Oppenheimer N, Schuber F, Potter BV. L. Biochemistry 2002; 41: 6744

20 Kudoh T, Fukuoka M, Ichikawa S, Murayama T, Ogawa Y, Hashii M, Higashida H, Kunerth S, Weber K, Guse AH, Potter BV. L, Matsuda A, Shuto S. J. Am. Chem. Soc. 2005; 127: 8846
21 Li L, Siebrands CC, Yang Z, Guse AH, Zhang L. Org. Biomol. Chem. 2010; 8: 1843
22 Guse AH, Gu X, Zhang L, Weber K, Krämer E, Yang Z, Jin H, Li Q, Carrier L, Zhang L. J. Biol. Chem. 2005; 280: 15952
23 Ashamu GA, Sethi JK, Galione A, Potter BV. L. Biochemistry 1997; 36: 9509
24 Xu L, Walseth TF, Slama JT. J. Med. Chem. 2005; 48: 4177
25 Zhang FJ, Yamada S, Gu QM, Sih CJ. Bioorg. Med. Chem. Lett. 1996; 6: 1203

26a Qi N, Jung K, Wang M, Na LX, Yang ZJ, Zhang LR, Guse AH, Zhang LH. Chem. Commun. 2011; 47: 9462
26b Xu J, Yang Z, Dammermann W, Zhang L, Guse AH, Zhang LH. J. Med. Chem. 2006; 49: 5501

27 Lee HC, Aarhus R. Cell Regul. 1991; 2: 203

28a Crespo-Hernandez CE, Cohen B, Hare PM, Kohler B. Chem. Rev. 2004; 104: 1977
28b Kierdaszuk B, Modrak-Wojcik A, Wierzchowski J, Shugar D. Biochim. Biophys. Acta 2000; 1476: 109
28c Börresen HC. Acta Chem. Scand. 1963; 17: 2359
28d Longworth JW, Rahn RO, Shulman RG. J. Chem. Phys. 1966; 45: 2930

29 Haluszczak J, Macdonald SJ. F, Migaud ME. Org. Biomol. Chem. 2011; 9: 2821

30a Woenckhaus C, Zumpe P. Z. Naturforsch., B 1968; 23: 484
30b Woenckhaus C, Pfleiderer G. Biochem. Zeitschrift 1965; 341: 495
30c Woenckhaus C. Chem. Ber. 1964; 97: 2439

31a Yoshikawa M, Kato T, Takenishi T. Tetrahedron Lett. 1967; 5065
31b Yoshikawa M, Kato T, Takenishi T. Bull. Chem. Soc. Jpn. 1969; 42: 3505

32 Ikemoto T, Haze A, Hatano H, Kitamoto Y, Ishida M, Nara K. Chem. Pharm. Bull. 1995; 43: 210
33 General Procedure for the Yoshikawa Phosphorylation: Prior to reactions, deprotected nucleosides were dissolved in MilliQ water, solutions frozen and freeze-dried. The powdered nucleoside (100 mg) was dissolved in minimum amount of triethylphosphate and heated with a heatgun until the solution became clear. When the solution cooled to r.t., phosphorus oxychloride was added (3 equiv) and the reaction was left stirring until completion. The reaction’s progress was traced by HPLC [SAX anion-exchange column, 50 mM ammonium formate (AF) buffer with 10% MeOH, pH 5]. Once complete, the reaction was quenched by the addition of ice or cold TEAB buffer pH 8. The triethylphosphate was removed by washing the aqueous solution with three portions of ice-cold CHCl₃. The crude reaction mixture was then frozen and subsequently freeze-dried, and isolation of the phosphorylated product was performed using a reverse-phase column (Varian: prepacked C18 column); product elution was carried out using a linear gradient 5–90% of 10 mM AF (adjusted to pH 5) against MeOH. 1-N-(5′-Phosphato-β-d-ribofuranosyl)benzimidazole (19): A 70% yield of compound 19 was achieved when purification was performed on reverse-phase column (Varian: prepacked C18 column), product elution was carried out using a linear gradient 5–90% of 10 mM AF (adjusted to pH 5) against MeOH. ¹H NMR (600 MHz, D₂O): δ = 9.40 (s, 1 H), 7.87–7.93 (m, 1 H), 7.78–7.86 (m, 1 H), 7.58–7.66 (m, 2 H), 6.27 (d, J = 4.2 Hz, 1 H), 4.60 (t, J = 4.2 Hz, 1 H), 4.39–4.47 (m, 2 H), 4.20–4.27 (m, 1 H), 4.08–4.16 (m, 1 H). ¹³C NMR (150 MHz, D₂O): δ = 138.3, 131.3, 129.7, 127.2, 126.9, 115.0, 113.2, 90.9, 84.5 (d, J = 8.8 Hz), 75.1, 69.7, 63.7 (d, J = 4.7 Hz). ³¹P NMR (162 MHz, D₂O): δ = 0.21. HPLC: t _R = 12.32 min. MS (ES): m/z [M + H]⁺ calcd for C₁₂H₁₅N₂O₇P: 331.0695; found: 331.0703.
34 5-Phenyl-1-N-(5′-Phosphato-β-d-ribofuranosyl)-benzimidazole (20): A 62% isolated yield of compound 20 was achieved when purification was performed on reverse-phase column (Varian: prepacked C18 column), product elution was carried out using a linear gradient 5–90% of 10 mM AF (adjusted to pH 5) against MeOH. ¹H NMR (300 MHz, D₂O): δ = 8.54–8.66 (m, 1 H), 7.97 (m, 1 H), 7.79–7.87 (m, 1 H), 7.53–7.75 (m, 3 H), 7.41 (t, J = 7.3 Hz, 2 H), 7.31 (t, J = 7.3 Hz, 1 H), 6.08 (d, J = 6.2 Hz, 1 H), 4.55–4.62 (m, 1 H), 4.36–4.48 (m, 1 H), 4.22–4.33 (m, 1 H), 4.06–4.16 (m, 2 H). ³¹P NMR (121 MHz, D₂O): δ = 0.49. HPLC: t _R = 12.88 min. MS (ES): m/z [M – H]^– calcd for C₁₈H₁₈N₂O₇P: 405.0852; found: 405.0869.
35 2-(3′-Pyridyl)-1-N-(5′′-Phosphato-β-d-ribofuranosyl)-benzimidazole (21): A 25% yield of compound 21 was achieved when the initial purification was performed on ion-exchange resin (DEAE Sepharose Fast Flow) using gradient miliQ water against 0.1 M triethylamine formate (TEAF) at pH 5 with 10% of MeOH (0–100%) followed by reverse-phase purification (Varian: prepacked C18 column), product elution was carried out using a linear gradient 5–90% of 10 mM AF (adjusted to pH 5) against MeOH. ¹H NMR (300 MHz, D₂O): δ = 8.74 (s, 1 H), 8.64 (d, J = 4.2 Hz, 1 H), 8.08–8.17 (m, 1 H), 7.96 (d, J = 7.6 Hz, 1 H), 7.70 (d, J = 7.3 Hz, 1 H), 7.58 (dd, J = 5.1, 7.9 Hz, 1 H), 7.30–7.43 (m, 2 H), 5.80 (d, J = 7.7 Hz, 1 H), 4.82 (dd, J = 6.3, 7.6 Hz, 1 H), 4.35 (dd, J = 3.1, 6.3 Hz, 1 H), 4.10–4.16 (m, 1 H), 3.99–4.03 (m, 2 H). ¹³C NMR (100 MHz, D₂O): δ = 150.5, 149.0, 142.0, 138.7, 132.6, 125.6, 124.6, 124.4, 124.1, 119.1, 113.9, 89.0, 84.2 (d, J = 8.7 Hz), 70.7, 69.6, 64.1 (d, J = 4.8 Hz). ³¹P NMR (121 MHz, D₂O): δ = 2.24. HPLC: t _R = 15.38 min. MS (ES): m/z [M + H]⁺ calcd for C₁₇H₁₉N₃O₇P: 408.0961; found: 408.0952.
36 Mizuno Y, Itoh T, Saito K. J. Org. Chem. 1964; 29: 2611
37 Cramer F, Schaller H, Staab HA. Chem. Ber. 1961; 94: 1612
38 Zhang B, Bailey VC, Potter BV. L. J. Org. Chem. 2008; 73: 1693

39a Ko H, Fricks I, Ivanov AA, Harden TK, Jacobson KA. J. Med. Chem. 2007; 50: 2030
39b Crauste C, Périgaud C, Peyrottes S. J. Org. Chem. 2009; 74: 9165

40 General Procedure for the CDI-Mediated Pyrophosphate Bond Formation: Prior to the reaction a stock solution of NMN was prepared by dissolving NMN (100 mg) in anhyd DMF (1 ml) and anhyd formamide (1 mL). CDI (2.5 equiv) and Et₃N (2 equiv) were then added to a solution of nucleotide (1.2 equiv) in anhyd DMF (0.5 mL). The reaction was stirred for 12 h at r.t. The reaction was then quenched with anhyd MeOH and evaporated to dryness. The resulting solid was dissolved in new portion of anhyd DMF (0.5 mL) and a solution of NMN (1 equiv) was added. The reaction was followed by ³¹P NMR and once the imidazolate peak had disappeared, the reaction was diluted with MilliQ water and applied on DEAE sepharose. Isolation of the NAD analogues was performed using ion-exchange resin (DEAE Sepharose Fast Flow) using gradient MilliQ water against 0.1 M ammonium formate buffer (AF) at pH 5 with 10% of MeOH (0–100%).
41 Nicotinamide Benzimidazole Dinucleotide (25): The product was isolated after 48 h in 32% of yield. ¹H NMR (400 MHz, D₂O): δ = 9.12 (s, 1 H), 8.98 (d, J = 6.2 Hz, 1 H), 8.61 (d, J = 8.1 Hz, 1 H), 8.38 (s, 1 H), 7.94–8.07 (m, 1 H), 7.58 (d, J = 7.58, 15.6 Hz, 2 H), 7.25–7.34 (m, 3 H), 6.98 (d, J = 7.8 Hz, 1 H), 5.91 (dd, J = 5.9, 9.3 Hz, 2 H), 3.98–4.51 (m, 10 H). ¹³C NMR (100 MHz, D₂O): δ = 180.0, 171.0, 145.4, 142.1, 142.1, 139.7, 133.4, 129.9, 128.5, 124.2, 123.5, 121.6, 119.1, 114.9, 111.5, 99.9, 88.2 (d), 83.7 (d), 77.5, 72.9, 70.4, 70.10, 65.59 (d), 64.81 (d). ³¹P NMR (162 MHz, D₂O): δ = –10.95 to –12.08 (m, P–O–P). MS (ES): m/z [M – H]^– calcd for C₂₃H₂₈N₄O₁₄P₂: 646.1077; found: 646.1078. HPLC: t _R = 7.17 min.
42 Ames BN. Methods in Enzymology: Complex Carbohydrates . Neufeld E, Ginsburg V. Academic Press; New York: 1966. Vol. VIII 115
43 Nicotinamide 5-Phenylbenzimidazole Dinucleotide (26): The product was isolated after 48 h in 43% of yield. ¹H NMR (400 MHz, D₂O): δ = 8.86 (s, 1 H), 8.67 (s, 1 H), 8.58 (s, 2 H), 8.09 (s, 1 H), 7.85 (s, 1 H), 7.29–7.68 (m, 9 H), 5.91 (s, 1 H), 5.52 (s, 1 H), 3.94–4.42 (m, 10 H). ³¹P NMR (162 MHz, D₂O): δ = –11.09 to –11.60 (m, P–O–P). HPLC: t _R = 8.87 min. MS (ES): m/z [M]⁺ calcd for C₂₉H₃₃N₄O₁₄P₂ ⁺: 723.1469; found: 723.1436.
44 Aplysia cyclase was purchased from Sigma-Aldrich. The incubation reactions were monitored by HPLC (SAX column, 5% MeOH; 50 mM KH₂PO₄, pH 4). The enzymatic assays were conducted in TEAB buffer (0.1 M, pH 7.2) and used 1 mL solution containing 100 mM of NAD⁺ analogues, and 10 μL of reconstituted enzyme in buffer (ca. 300 units/mL).
45 Pesnot T, Kempter J, Schemies J, Pergolizzi G, Rumpf T, Uciechowska U, Sippl W, Jung M, Wagner GK. J. Med Chem. 2011; 54: 3492
46 Dölle C, Rack JG. M, Ziegler M. FEBS J. 2013; 280: 3530